Source: Google NewsPublished on 2020-12-23
Related Articles:
- Neurocrine, Voyager Team Up to Develop VY-AADC for Parkinson’s Disease February 4, 2019 Neurocrine Biosciences and Voyager Therapeutics have joined efforts in a new strategic collaboration to further develop and market Voyager’s gene therapies VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia. With this partnership, Neurocrine Biosciences will apply its expertise in neuroscience, drug development, and commercialization to help expedite the development of Voyager’s gene therapy programs. “We are excited to collaborate…
- Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- Parkinson's Disease News - Editor's Picks (Archive 2016.11) March 17, 2017 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Neurons Paralyze Us During REM SleepIt will also be most useful in the study of Parkinson’s disease, since these pathologies are related. This work was published on December 12, 2016 on the website of the journal Brain.…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Parkinson’s Gene Therapy Now in Phase 2 Trial, VY-AADC, Continues to Show Motor Benefits, Voyager Says July 20, 2018 Voyager Therapeutics announced likely plans to request approval of VY-AADC as a Parkinson’s gene therapy, based on feedback it received from the U.S. Food and Drug Administration (FDA) and eventual outcomes of a newly opened Phase 2 trial. The company also reported that its Phase 1 trial of VY-AADC showed improvements in patients’ motor function and reduced use of medications, among other benefits, further supporting a…
- Voyager’s AADC Gene Therapy Shows Promise as Maintenance Therapy for Parkinson’s October 26, 2017 Voyager Therapeutics’ new clinical data on VY-AADC01 as a maintenance therapy for advanced Parkinson’s disease shows improvement in patients’ motor function after just one dose, and with meaningfully lower doses of oral levodopa. The company presented ongoing Phase 1b trial (NCT01973543) results at the Oct. 17-20 Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, in a talk titled “Intraputaminal AADC gene…
- Voyager’s Gene Therapy Improves Parkinson’s Patients’ Movement Over Long Term, Trial Shows March 12, 2018 A single administration of Voyager Therapeutics gene therapy improves advanced Parkinson’s patients’ movement up to three years later, a Phase 1b trial indicates. Voyager designed VY-AADC01 to deliver the aromatic L-amino acid decarboxylase (AADC) gene to a specific brain region, the putamen. The gene provides instructions for the production of the AADC enzyme. The enzyme is responsible for converting the treatment levodopa into…
- Voyager Recruits Patients for Phase 1 Trial Testing VY-AADC01 Gene Therapy Delivery November 21, 2017 Voyager Therapeutics announced it’s recruiting participants for the company’s new Phase 1 clinical trial to test a new approach for their gene therapy VY-AADC01 in Parkinson’s disease patients. The company has also released updates to its ongoing Phase 1b trial testing VY-AADC01 and highlighted its preclinical programs focusing on amyotrophic lateral sclerosis, Huntington’s disease, and Friedreich’s ataxia. AAV is a small virus capable…
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Phase 2 Trial of Gene Therapy VY-AADC to Include More Parkinson’s Patients January 9, 2019 The ongoing Phase 2 study of the gene therapy VY-AADC will enroll more Parkinson’s disease patients than originally planned, Voyager Therapeutics announced. The company’s revised trial protocol will include more patients — up from 75 to 100 — in the RESTORE-1 Phase 2 clinical trial (NCT03562494). Voyager also is planning to conduct a parallel Phase 3 study named RESTORE-2, with similar…
- FDA Grants Regenerative Medicine Advanced Therapy Designation to VY-AADC for Parkinson’s June 25, 2018 The U.S. Food and Drug Administration granted Voyager Therapeutics’ gene therapy candidate VY-AADC regenerative medicine advanced therapy (RMAT) designation for the treatment of therapy-resistant motor fluctuations in Parkinson’s patients. The RMAT designation, recently created by the FDA, is given to regenerative medicine products intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and that have early…
- Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson’s Disease January 24, 2018 Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson’s disease. The trial follows approval by the U.S. Food and Drug Administration of the company’s investigational new drug (IND) application for VY-AADC. “Following institutional review board approval and patient screening at clinical referral and surgical sites, we…
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- First Patient Dosed with VY-AADC Gene Therapy in Parkinson’s Phase 2 Trial December 11, 2018 Voyager Therapeutics has begun patient dosing in a Phase 2 trial testing its investigational VY-AADC gene therapy in Parkinson’s patients whose motor symptoms are not responding adequately to oral medication. The trial, called RESTORE-1 (NCT03562494), is recruiting participants across seven sites in the United States. VY-AADC is a therapy that delivers the DDC gene, which provides instructions for making the AADC enzyme, directly to brain…
- Phase 1b Trial of VY-AADC01 Gene Therapy for Advanced Parkinson’s Disease Shows Positive Results September 8, 2017 An ongoing Phase 1b trial of VY-AADC01, a gene therapy for the treatment of advanced Parkinson’s disease (PD), is showing positive results, including improvement of motor function and activities of daily living, durable clinical effects, and good tolerability. The announcement was made by Voyager Therapeutics, the gene therapy company specialized in neurological diseases that is leading the trial. In data previously presented at…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- AbbVie, Voyager Team Up to Develop Antibodies for Parkinson’s, Other Diseases February 27, 2019 AbbVie and Voyager Therapeutics have extended their collaboration to co-develop and commercialize antibodies that target the toxic forms of alpha-synuclein to treat Parkinson’s disease and other synucleinopathies. The collaboration will combine AbbVie’s expertise in monoclonal antibodies with Voyager’s gene therapy platform to deliver antibodies across the blood-brain barrier using a one-time injection into the blood. The blood-brain barrier is a semipermeable membrane that protects the…
- FDA: Data Manipulation Reported in Recently Approved Gene Therapy for SMA August 7, 2019 According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved. In a press release, Peter Marks, MD, PhD, director of FDA’s Center for Biologics Evaluation and Research stated that…
- What’s New in Parkinson’s: December 2020 December 31, 2020 From tomatoes to live-streaming brain activity to genetic testing studies, news from the Parkinson’s field is as varied as it is encouraging this month. Here are some of the most important articles, podcasts, research, and living well stories happening as we wrap up 2020. Let us know if we missed anything important. Happy reading and happy new year! PARKINSON’S ARTICLES…
- #AANAM — Investigational VY-AADC01 Gene Therapy Provides Benefits for Parkinson’s Patients, Phase 1 Data Show May 7, 2019 A single-dose infusion of VY-AADC01, an investigational gene therapy, improves motor function and reduces the need for antiparkinsonian medications in advanced Parkinson’s disease patients, results from the Phase 1 PD-1102 clinical trial show. Trial findings were presented in a scientific poster, titled “PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…